Guess which ASX 200 share is up 7% after smashing FY24 guidance

This growing company has outperformed expectations in FY 2024 with another impressive 12 months.

| More on:
Ecstatic woman looking at her phone outside with her fist pumped.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is roaring higher on Tuesday morning.

At the time of writing, the ASX 200 share is up 7% to $25.79.

Why is this ASX 200 share jumping?

Investors have been buying the company's shares this morning after it released an update on its performance in FY 2024.

According to the release, fourth quarter unaudited revenue came in at approximately US$142 million (AU$218 million). This represents an increase of 46% over the prior year corresponding quarter and a 5% lift quarter-over-quarter.

Telix's revenue is currently generated predominantly from sales of Illuccix, its diagnostic radiopharmaceutical for prostate cancer PET2 imaging.

In light of this strong finish to the year, the ASX 200 share has outperformed its guidance for FY 2024.

It revealed that total unaudited full year revenue is up 55% year on year to approximately US$517 million (AU$783 million). This compares to its guidance range of US$490 million to US$510 million for the year.

Another positive is that the therapeutic and diagnostic radiopharmaceuticals company's investment into research and development (R&D) remains in line with guidance and is being funded by earnings generated from product sales.

Management commentary

The ASX 200 share's managing director and group chief executive officer, Dr. Christian Behrenbruch, was pleased with the company's performance in the fourth quarter. He said:

This has been another great quarter of commercial performance. Strong sales of Illuccix have led Telix to close out the year with revenue above guidance, while significantly progressing our strategic priorities. Boosting our balance sheet and the Nasdaq listing were major corporate milestones. The acquisition of FAP-targeting assets is a major addition to our superb product pipeline.

We are well-positioned for significant expansion, including planned launches of multiple imaging products in key markets and advancing late-stage therapeutic assets into pivotal trials. 2025 is shaping up to be transformative year for Telix.

Those late-stage therapeutic assets include its glioblastoma therapy candidate, TLX101. Based on positive feedback from its meeting with the US FDA, Telix is planning to move forward with an investigational new drug (IND) submission in the first half of 2025.

In addition, it will be progressing its kidney cancer therapy candidate, TLX250, and its prostate cancer therapy candidate, TLX591.

Telix also advised that intends to provide its FY 2025 guidance when it reports its audited FY 2024 results on 20 February 2025.

Following today's gain, the Telix share price is now up 140% over the past 12 months.

Should you invest $1,000 in Betashares Nasdaq 100 Etf right now?

Before you buy Betashares Nasdaq 100 Etf shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Betashares Nasdaq 100 Etf wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 136% in a year, why is this ASX 200 share slipping on Wednesday?

The high-performing ASX 200 share is expanding its product pipeline.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Meet the dirt cheap ASX 200 stock that could rocket 75%

Bell Potter thinks investors should be snapping up this stock while it is down in the dumps.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

This ASX 200 healthcare share is sinking 9% on CEO exit

Investors are selling off this stock on Tuesday. Here's what you need to know.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why is the CSL share price falling on Monday?

The ASX 200 biotech stock has lost 9% of its value since the start of the new year.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are Sonic Healthcare or CSL shares a better buy?

Which of these healthcare giants is a better buy?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Dividend Investing

Hoping to bag the boosted dividend from CSL shares? Here's your deadline…

The ASX 200 biotech is rewarding investors with a 9% higher interim dividend this year.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares rated as top buys

Are these two names healthy choices for your portfolio? Let's see.

Read more »